{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:29:48Z","timestamp":1788521388632,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T00:00:00Z","timestamp":1636761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T00:00:00Z","timestamp":1636761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Bern"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Amongst others, [<jats:sup>68<\/jats:sup>Ga]Ga-PSMA-11 and [<jats:sup>18<\/jats:sup>F]PSMA-1007 are available for the detection of recurrent prostate cancer (rPC). There are currently limited data comparing the performance of these two radioligands with respect to clinical outcomes or their cost efficacy, which this study aims to address.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Two hundred and forty-four patients undergoing PSMA PET\/CT for rPC were retrospectively analysed for this study (one hundred and twenty two\u00a0with each radiopharmaceutical) to generate rates of PET positivity, negativity and unclear findings. Patients underwent follow-up to determine the rate of additional examinations and to confirm PET findings. A Markov chain decision analysis was implemented to model clinical decision-making processes and to analyse clinical performance of the two tracers. We determine their clinical cost efficacies using cost data from several countries where both radiotracers are in routine use.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The PET positivity rate was non-significantly higher for [<jats:sup>18<\/jats:sup>F]PSMA-1007 compared to [<jats:sup>68<\/jats:sup>Ga]Ga-PSMA-11 (91.8% vs. 86.9%, <jats:italic>p<\/jats:italic> = 0.68), whereas the rate of uncertain findings was significantly greater (17.2% vs. 8.25%, <jats:italic>p<\/jats:italic> = 0.02). The probability of a true positive finding was higher for [<jats:sup>68<\/jats:sup>Ga]Ga-PSMA-11 (0.90, 95% CI 0.70-0.98) vs. [<jats:sup>18<\/jats:sup>F]PSMA-1007 (0.81, 95% CI 0.66\u20130.91). A significantly (<jats:italic>p<\/jats:italic> &lt; 0.0001) higher PPV for [<jats:sup>68<\/jats:sup>Ga]Ga-PSMA-11 (0.99, 95% CI 0.99\u20131.0 vs. 0.86) was found compared to [<jats:sup>18<\/jats:sup>F]PSMA-1007 (0.86, 95% CI 0.82\u20131.00). Intervention efficacy analysis favoured [<jats:sup>68<\/jats:sup>Ga]Ga-PSMA-11, where the number needed to image (to achieve a true positive finding) was 10.58 and the number needed to image to harm (to achieve a false positive finding) was \u2212 8.08. A cost efficacy analysis favours [<jats:sup>68<\/jats:sup>Ga]Ga-PSMA-11 in three of the four jurisdictions analysed where health economic data was available (Switzerland, Israel, Australia) and [<jats:sup>18<\/jats:sup>F]PSMA-1007 in one jurisdiction (Denmark).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The analysis reveals a non-significantly higher PET positivity rate for [<jats:sup>18<\/jats:sup>F]PSMA-1007, but finds significantly greater rates of uncertain findings and false positive findings when compared to [<jats:sup>68<\/jats:sup>Ga]Ga-PSMA-11. We find differences in the two tracers in terms of clinical performance and cost efficacy. The method presented herein is generalisable and can be used with clinical or cost data for other countries or tracers.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-021-05620-9","type":"journal-article","created":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T08:02:51Z","timestamp":1636790571000},"page":"4252-4261","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Comparing the clinical performance and cost efficacy of [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 in the diagnosis of recurrent prostate cancer: a Markov chain decision analysis"],"prefix":"10.1007","volume":"49","author":[{"given":"Ian","family":"Alberts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Mingels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helle D.","family":"Zacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Lanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Sch\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Rominger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Zwahlen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Afshar-Oromieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,13]]},"reference":[{"key":"5620_CR1","doi-asserted-by":"publisher","unstructured":"Afshar-Oromieh A, da Cunha ML, Wagner J, Haberkorn U, Debus N, Weber W, et al. Performance of [68Ga]Ga-PSMA-11 PET\/CT in patients with recurrent prostate cancer after prostatectomy\u2014a multi-centre evaluation of 2533 patients. Eur J Nuclear Med Mol Imaging. 2021https:\/\/doi.org\/10.1007\/s00259-021-05189-3","DOI":"10.1007\/s00259-021-05189-3"},{"key":"5620_CR2","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208\u201316. https:\/\/doi.org\/10.1016\/S0140-6736(20)30314-7.","journal-title":"Lancet."},{"key":"5620_CR3","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","volume":"40","author":"A Afshar-Oromieh","year":"2013","unstructured":"Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nuclear Med Mol Imaging. 2013;40:486\u201395. https:\/\/doi.org\/10.1007\/s00259-012-2298-2.","journal-title":"Eur J Nuclear Med Mol Imaging."},{"key":"5620_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7150\/thno.37894","volume":"10","author":"RA Werner","year":"2020","unstructured":"Werner RA, Derlin T, Lapa C, Sheikbahaei S, Higuchi T, Giesel FL, et al. 18F-Labeled, PSMA-Targeted radiotracers: leveraging the advantages of radiofluorination for prostate cancer molecular imaging. Theranostics. 2020;10:1\u201316. https:\/\/doi.org\/10.7150\/thno.37894.","journal-title":"Theranostics."},{"key":"5620_CR5","doi-asserted-by":"publisher","unstructured":"Alberts I, Huenermund JN, Sachpekidis C, Zacho HD, Mingels C, Dijkstra L, et al. Combination of forced diuresis with additional late imaging in 68Ga-PSMA-11 PET\/CT \u2013 effects on lesion visibility and radiotracer uptake. J Nuclear Med. 2021. https:\/\/doi.org\/10.2967\/jnumed.120.257741","DOI":"10.2967\/jnumed.120.257741"},{"key":"5620_CR6","doi-asserted-by":"publisher","unstructured":"Alberts I, Sachpekidis C, Gourni E, et al. Dynamic patterns of [68Ga]Ga-PSMA-11 uptake in recurrent prostate cancer lesions. Eur J Nucl Med Mol Imaging. 2020;47: 160\u20137. https:\/\/doi.org\/10.1007\/s00259-019-04545-8","DOI":"10.1007\/s00259-019-04545-8"},{"key":"5620_CR7","doi-asserted-by":"publisher","unstructured":"Alberts IL, Seide SE, Mingels C, Bohn KP, Shi K, Zacho HD, et al. Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis. European J Nuclear Med Mol Imaging. 2021. https:\/\/doi.org\/10.1007\/s00259-021-05210-9","DOI":"10.1007\/s00259-021-05210-9"},{"key":"5620_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2967\/jnumed.119.229187","volume":"61","author":"I Rauscher","year":"2020","unstructured":"Rauscher I, Kronke M, Konig M, Gafita A, Maurer T, Horn T, et al. Matched-pair comparison of (68)Ga-PSMA-11 PET\/CT and (18)F-PSMA-1007 PET\/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy. J Nuclear Med. 2020;61:51\u20137. https:\/\/doi.org\/10.2967\/jnumed.119.229187.","journal-title":"J Nuclear Med."},{"key":"5620_CR9","doi-asserted-by":"publisher","unstructured":"Gr\u00fcnig H, Maurer A, Thali Y, Kovacs Z, Strobel K, Burger IA, et al. Focal unspecific bone uptake on [18F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging. Eur J Nuclear Med Mol Imaging. 2021.https:\/\/doi.org\/10.1007\/s00259-021-05424-x","DOI":"10.1007\/s00259-021-05424-x"},{"key":"5620_CR10","doi-asserted-by":"publisher","first-page":"511","DOI":"10.2967\/jnumed.118.217653","volume":"60","author":"Y Yin","year":"2019","unstructured":"Yin Y, Werner RA, Higuchi T, Lapa C, Pienta KJ, Pomper MG, et al. Follow-up of lesions with equivocal radiotracer uptake on PSMA-targeted PET in patients with prostate cancer: predictive values of the PSMA-RADS-3A and PSMA-RADS-3B categories. J Nuclear Med. 2019;60:511\u20136. https:\/\/doi.org\/10.2967\/jnumed.118.217653.","journal-title":"J Nuclear Med."},{"key":"5620_CR11","doi-asserted-by":"publisher","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7-30. https:\/\/doi.org\/10.3322\/caac.21590","DOI":"10.3322\/caac.21590"},{"key":"5620_CR12","doi-asserted-by":"publisher","unstructured":"Siegel DA, O\u2019Neil ME, Richards TB, Dowling NF, HK W. Prostate cancer incidence and survival, by stage and race\/ethnicity \u2014 United States, 2001\u20132017. MMWR Morb Mortal Wkly Rep 2020. 2020;69:1473-80. https:\/\/doi.org\/10.15585\/mmwr.mm6941a1","DOI":"10.15585\/mmwr.mm6941a1"},{"key":"5620_CR13","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2967\/jnumed.120.260455","volume":"62","author":"G Carlucci","year":"2021","unstructured":"Carlucci G, Ippisch R, Slavik R, Mishoe A, Blecha J, Zhu S. 68Ga-PSMA-11 NDA Approval: A Novel and Successful Academic Partnership. J Nuclear Med. 2021;62:149. https:\/\/doi.org\/10.2967\/jnumed.120.260455.","journal-title":"J Nuclear Med."},{"key":"5620_CR14","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s00259-017-3852-8","volume":"45","author":"M Sathekge","year":"2018","unstructured":"Sathekge M, Lengana T, Maes A, Vorster M, Zeevaart J, Lawal I, et al. 68Ga-PSMA-11 PET\/CT in primary staging of prostate carcinoma: preliminary results on differences between black and white South-Africans. Eur J Nuclear Med Mol Imaging. 2018;45:226\u201334. https:\/\/doi.org\/10.1007\/s00259-017-3852-8.","journal-title":"Eur J Nuclear Med Mol Imaging."},{"key":"5620_CR15","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1470-2045(21)00093-0","volume":"22","author":"K Gourd","year":"2021","unstructured":"Gourd K, Collingridge D. Improving the view: the need for global action on universal access to cancer imaging. Lancet Oncol. 2021;22:422\u20133. https:\/\/doi.org\/10.1016\/S1470-2045(21)00093-0.","journal-title":"Lancet Oncol."},{"key":"5620_CR16","doi-asserted-by":"publisher","first-page":"S144","DOI":"10.1016\/j.ijrobp.2020.07.888","volume":"108","author":"NR Parikh","year":"2020","unstructured":"Parikh NR, Johnson D, Raldow A, Steinberg ML, Czernin J, Nickols NG, et al. Cost-effectiveness of 68Ga-PSMA-11 PET\/CT in prostate cancer patients with biochemical recurrence. Int J Radiat Oncol Biol Phys. 2020;108:S144\u20135. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.07.888.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"5620_CR17","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.eururo.2020.11.043","volume":"79","author":"RE de Feria Cardet","year":"2021","unstructured":"de Feria Cardet RE, Hofman MS, Segard T, Yim J, Williams S, Francis RJ, et al. Is Prostate-specific Membrane Antigen Positron Emission Tomography\/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial. Eur Urol. 2021;79:413\u20138. https:\/\/doi.org\/10.1016\/j.eururo.2020.11.043.","journal-title":"Eur Urol."},{"key":"5620_CR18","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10585-020-10027-1","volume":"37","author":"LG Gordon","year":"2020","unstructured":"Gordon LG, Elliott TM, Joshi A, Williams ED, Vela I. Exploratory cost-effectiveness analysis of 68Gallium-PSMA PET\/MRI-based imaging in patients with biochemical recurrence of prostate cancer. Clin Exp Metastasis. 2020;37:305\u201312. https:\/\/doi.org\/10.1007\/s10585-020-10027-1.","journal-title":"Clin Exp Metastasis."},{"key":"5620_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f1049","volume":"346","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ Br Med J. 2013;346: f1049. https:\/\/doi.org\/10.1136\/bmj.f1049.","journal-title":"BMJ Br Med J."},{"key":"5620_CR20","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2165\/00019053-199813040-00003","volume":"13","author":"A Briggs","year":"1998","unstructured":"Briggs A, Sculpher M. An Introduction to Markov Modelling for Economic Evaluation. PharmacoEconomics. 1998;13:397\u2013409. https:\/\/doi.org\/10.2165\/00019053-199813040-00003.","journal-title":"PharmacoEconomics."},{"key":"5620_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/a-1044-1855","volume":"59","author":"I Alberts","year":"2020","unstructured":"Alberts I, Sachpekidis C, Fech V, Rominger A, Afshar-Oromieh A. PSMA-negative prostate cancer and the continued value of choline-PET\/CT. Nuklearmedizin Nuclear Med. 2020;59:1. https:\/\/doi.org\/10.1055\/a-1044-1855.","journal-title":"Nuklearmedizin Nuclear Med."},{"key":"5620_CR22","doi-asserted-by":"publisher","first-page":"e0211633","DOI":"10.1371\/journal.pone.0211633","volume":"14","author":"M Bekker-Nielsen Dunbar","year":"2019","unstructured":"Bekker-Nielsen Dunbar M, Finnie TJR, Sloane B, Hall IM. Methods for calculating credible intervals for ratios of beta distributions with application to relative risks of death during the second plague pandemic. PLoS ONE. 2019;14:e0211633. https:\/\/doi.org\/10.1371\/journal.pone.0211633.","journal-title":"PLoS ONE."},{"key":"5620_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nrd1927","volume":"5","author":"DA Berry","year":"2006","unstructured":"Berry DA. Bayesian clinical trials. Nat Rev Drug Discov. 2006;5:27\u201336. https:\/\/doi.org\/10.1038\/nrd1927.","journal-title":"Nat Rev Drug Discov."},{"key":"5620_CR24","doi-asserted-by":"publisher","unstructured":"Velez EM, Desai B, Ji L, Quinn DI, Colletti PM, Jadvar H. Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria. Theranostics. 2020;10:3254-62. https:\/\/doi.org\/10.7150\/thno.39838","DOI":"10.7150\/thno.39838"},{"key":"5620_CR25","doi-asserted-by":"publisher","first-page":"e0240215","DOI":"10.1371\/journal.pone.0240215","volume":"15","author":"J Balayla","year":"2020","unstructured":"Balayla J. Prevalence threshold (varphie) and the geometry of screening curves. PLoS ONE. 2020;15:e0240215. https:\/\/doi.org\/10.1371\/journal.pone.0240215.","journal-title":"PLoS ONE."},{"key":"5620_CR26","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ."},{"key":"5620_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1471-2288-3-25","volume":"3","author":"P Whiting","year":"2003","unstructured":"Whiting P, Rutjes AWS, Reitsma JB, Bossuyt PMM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25. https:\/\/doi.org\/10.1186\/1471-2288-3-25.","journal-title":"BMC Med Res Methodol."},{"key":"5620_CR28","doi-asserted-by":"publisher","first-page":"1717030","DOI":"10.1080\/20016689.2020.1717030","volume":"8","author":"JA McDougall","year":"2020","unstructured":"McDougall JA, Furnback WE, Wang BCM, Mahlich J. Understanding the global measurement of willingness to pay in health. J Market Access Health Policy. 2020;8:1717030. https:\/\/doi.org\/10.1080\/20016689.2020.1717030.","journal-title":"J Market Access Health Policy."},{"key":"5620_CR29","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","volume":"354","author":"D Moher","year":"1999","unstructured":"Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet. 1999;354:1896\u2013900. https:\/\/doi.org\/10.1016\/S0140-6736(99)04149-5.","journal-title":"Lancet."},{"key":"5620_CR30","doi-asserted-by":"publisher","first-page":"786","DOI":"10.2967\/jnumed.118.219501","volume":"60","author":"TA Hope","year":"2019","unstructured":"Hope TA, Goodman JZ, Allen IE, Calais J, Fendler WP, Carroll PR. Metaanalysis of 68Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology. J Nuclear Med. 2019;60:786. https:\/\/doi.org\/10.2967\/jnumed.118.219501.","journal-title":"J Nuclear Med."},{"key":"5620_CR31","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1007\/s00259-018-4089-x","volume":"45","author":"K Rahbar","year":"2018","unstructured":"Rahbar K, Afshar-Oromieh A, Seifert R, Wagner S, Schafers M, Bogemann M, et al. Diagnostic performance of (18)F-PSMA-1007 PET\/CT in patients with biochemical recurrent prostate cancer. Eur J Nuclear Med Mol Imaging. 2018;45:2055\u201361. https:\/\/doi.org\/10.1007\/s00259-018-4089-x.","journal-title":"Eur J Nuclear Med Mol Imaging."},{"key":"5620_CR32","doi-asserted-by":"publisher","first-page":"362","DOI":"10.2967\/jnumed.118.212233","volume":"60","author":"FL Giesel","year":"2019","unstructured":"Giesel FL, Knorr K, Spohn F, Will L, Maurer T, Flechsig P, et al. Detection Efficacy of (18)F-PSMA-1007 PET\/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. J Nucl Med. 2019;60:362\u20138. https:\/\/doi.org\/10.2967\/jnumed.118.212233.","journal-title":"J Nucl Med."},{"key":"5620_CR33","doi-asserted-by":"publisher","unstructured":"Sprute K, Kramer V, Koerber S, Meneses M, Fernandez R, Soza-Ried C, et al. Diagnostic accuracy of 18 F-PSMA-1007 PET\/CT imaging for lymph node staging of prostate carcinoma in primary and biochemical recurrence J Nuclear Med. 2020. https:\/\/doi.org\/10.2967\/jnumed.120.246363","DOI":"10.2967\/jnumed.120.246363"},{"key":"5620_CR34","doi-asserted-by":"publisher","unstructured":"Giesel FL, Knorr K, Spohn F, Will L, Maurer T, Flechsig P, et al. Detection efficacy of [18F]-PSMA-1007 PET\/CT in 251 Patients with biochemical recurrence after radical prostatectomy. J Nuclear Med. 2018. https:\/\/doi.org\/10.2967\/jnumed.118.212233","DOI":"10.2967\/jnumed.118.212233"},{"key":"5620_CR35","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.2967\/jnumed.117.196683","volume":"58","author":"L Emmett","year":"2017","unstructured":"Emmett L, van Leeuwen PJ, Nandurkar R, Scheltema MJ, Cusick T, Hruby G, et al. Treatment outcomes from 68Ga-PSMA PET\/CT\u2013informed salvage radiation treatment in men with rising PSA after radical prostatectomy: prognostic value of a negative PSMA PET. J Nuclear Med. 2017;58:1972. https:\/\/doi.org\/10.2967\/jnumed.117.196683.","journal-title":"J Nuclear Med."},{"key":"5620_CR36","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1001\/jama.2016.19970","volume":"317","author":"SN Goodman","year":"2017","unstructured":"Goodman SN, Schneeweiss S, Baiocchi M. Using design thinking to differentiate useful from misleading evidence in observational research. JAMA. 2017;317:705\u20137. https:\/\/doi.org\/10.1001\/jama.2016.19970.","journal-title":"JAMA."},{"key":"5620_CR37","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1177\/0272989X05280562","volume":"25","author":"N Hawkins","year":"2005","unstructured":"Hawkins N, Sculpher M, Epstein D. Cost-Effectiveness Analysis of Treatments for Chronic Disease: Using R to Incorporate Time Dependency of Treatment Response. Med Decis Making. 2005;25:511\u20139. https:\/\/doi.org\/10.1177\/0272989X05280562.","journal-title":"Med Decis Making."},{"key":"5620_CR38","doi-asserted-by":"publisher","unstructured":"Kuten J, Dekalo S, Mintz I, Yossepowitch O, Mano R, Even-Sapir E. The significance of equivocal bone findings in staging PSMA imaging in the preoperative setting: validation of the PSMA-RADS version 1.0. EJNMMI Research. 2021;11:3. https:\/\/doi.org\/10.1186\/s13550-020-00745-8","DOI":"10.1186\/s13550-020-00745-8"},{"key":"5620_CR39","doi-asserted-by":"publisher","unstructured":"Spratt DE, McHugh DJ, Morris MJ, Morgans AK. Management of Biochemically Recurrent Prostate Cancer: Ensuring the Right Treatment of the Right Patient at the Right Time. Am Soc Clin Oncol Educ Book. 2018:355-62. https:\/\/doi.org\/10.1200\/EDBK_200319","DOI":"10.1200\/EDBK_200319"},{"key":"5620_CR40","doi-asserted-by":"publisher","unstructured":"Giammarile F, Fanti S. Comments to \u201cSurvey by the ANSM of the imaging protocol, detection rate, and safety of 68Ga-PSMA-11 PET\/CT\u201d. European Journal of Nuclear Medicine and Molecular Imaging. 2021. https:\/\/doi.org\/10.1007\/s00259-021-05292-5","DOI":"10.1007\/s00259-021-05292-5"},{"key":"5620_CR41","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.nucmedbio.2020.01.005","volume":"80\u201381","author":"BJB Nelson","year":"2020","unstructured":"Nelson BJB, Wilson J, Richter S, Duke MJM, Wuest M, Wuest F. Taking cyclotron 68Ga production to the next level: Expeditious solid target production of 68Ga for preparation of radiotracers. Nuclear Med Biol. 2020;80\u201381:24\u201331. https:\/\/doi.org\/10.1016\/j.nucmedbio.2020.01.005.","journal-title":"Nuclear Med Biol."},{"key":"5620_CR42","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.2967\/jnumed.118.225250","volume":"60","author":"S Piron","year":"2019","unstructured":"Piron S, De Man K, Van Laeken N, D\u2019Asseler Y, Bacher K, Kersemans K, et al. Radiation dosimetry and biodistribution of 18F-PSMA-11 for PET imaging of prostate cancer. J Nuclear Med. 2019;60:1736. https:\/\/doi.org\/10.2967\/jnumed.118.225250.","journal-title":"J Nuclear Med."}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-021-05620-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-021-05620-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-021-05620-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T17:04:33Z","timestamp":1664557473000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-021-05620-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,13]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["5620"],"URL":"https:\/\/doi.org\/10.1007\/s00259-021-05620-9","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,13]]},"assertion":[{"value":"23 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was performed in accordance with the Helsinki declaration. The study was approved by the institutional review board (IRB) KEK ID 2020-01162.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}